clinical trial · NCT02157077
Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration
Centre Hospitalier Intercommunal Creteil·phase3·completed·n = 84
Macular DegenerationWet Macular DegenerationRetinal DegenerationRetinal DiseasesEye DiseasesAflibercept
brief summary
The purpose of the current study is to evaluate the ability of Eylea to induce a regression of PED height on patients previously extensively treated by Lucentis. The regimen proposed for this study is the 3 monthly injection followed by a 6 weeks interval injection until week 26.
started
Dec 1, 2013
primary completion
Dec 1, 2015
completion
Dec 1, 2015
last updated
Oct 27, 2026
detailed description
The regimen proposed for this study is the 3 monthly injection followed by a 6 weeks interval injection until week 26.
official title
A Phase III b, Multicenter Study of the Efficacy and Safety of Aflibercept Switch in Patients With Exudative AMD With Detachment of the Retinal Pigment Epithelium and Previously Treated With Ranibizumab Intravitreal Injection. (ARI2)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol